From the publishers of JADPRO

MPN Resource Center

Advertisement

Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data

Last Updated: Monday, June 29, 2020

Results of a new analysis of real-world data—including 589 patients with ruxolitinib-treated myelofibrosis—showed that 65 patients (11%) developed myeloid blast phase, of which 61 patients discontinued ruxolitinib at blast phase diagnosis, at a median period of 1.2 years (range, 0.1-6.8) after starting the therapy. Incidence of transformation to blast phase was significantly lower in intermediate-1 risk patients compared with intermediate-2/high-risk patients. After a median follow-up of 3 years from ruxolitinib start, rates of transformation in patients with primary and secondary myelofibrosis were comparable.

Hematological Oncology
Advertisement
News & Literature Highlights

British Journal of Haematology

‘MPN Genomic Calculator’: real‐life use in a young population with essential thrombocythaemia

Leukemia

Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

Thrombosis Research

Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample

British Journal of Haemtology

Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis

Cancer Medicine

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition

Expert Review of Hematology

Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies

Annals of Hematology

Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms

Clinical Lymphoma Myeloma and Leukemia

Mortality and causes of death of patients with polycythemia vera: analysis of the REVEAL prospective, observational study

Advertisement
Advertisement